Immunitor publishes review on mucosal AIDS vaccines

The link to the abstract of Immunitors publication can be found on PubMed, the website of the National Library of Medicine based at the National Institutes of Health, NIH, Bethesda, MD, USA. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14733732&dopt=Abstract

(PRWEB) January 28, 2004 --Immunitor announces the publication of the latest update on progress in the area of AIDS vaccines (Bourinbaiar et al., Viral Immunology 2003; 16(4): 427-45). Viral Immunology is a peer-reviewed scientific journal published by Mary Ann Liebert Inc. Publishers (http://www.liebertpub.com/VIM/default1.asp). Viral Immunology focuses on the growing body of research in viral immunology, with papers on clinical, veterinary, and laboratory research. Topics covered include human and animal viral immunology; research and development of viral vaccines, including field trials; immunological characterization of viral components; virus-based immunological diseases, including autoimmune syndromes; viral pathogenesis; viral diagnostics; tumor and cancer immunology with virus as the primary factor; and viral immunology methods.

The link to the abstract of Immunitors publication can be found on PubMed, the website of the National Library of Medicine based at the National Institutes of Health, NIH, Bethesda, MD, USA. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14733732&dopt=Abstract

In the article Immunitor scientists argue that all obvious approaches to making AIDS vaccines have been tried in the past two decades without much success. Conventional envelope-based antibody-inducing vaccines do not appear to hold promise, and broadly-neutralizing antibodies are now being searched as an alternative to the failed approach with subunit vaccines. The current consensus is that cellular immune responses, especially those mediated by CD8 cytotoxic/suppressor (CTL) and CD4 helper T lymphocytes, are needed to control HIV. Vaccines capable of inducing cell-mediated responses are, therefore, considered critical for controlling the spread of HIV. DNA-based vaccines triggering CTL reaction are currently thought to be an answer, but will they fulfill the promise? (see for current debate on this issue at following links: http://www.sciencemag.org/cgi/content/summary/303/5656/316; http://www.voanews.com/article.cfm?objectID=4F46362D-3239-4F5F-89154FA3719D1C71
http://edition.cnn.com/2004/HEALTH/conditions/01/15/aids.vaccine.ap/
http://story.news.yahoo.com/news?tmpl=story&cid=541&ncid=751&e=3&u=/ap/20040116/ap_on_he_me/aids_vaccine

It is clear that new thinking and a revision of prevailing dogmas needs to be in place if we really want a vaccine that works. The review provides a critical assessment of the state of the art and analyzes what is known and what is still has to be discovered. The focus of the review is primarily on mucosal vaccines-a relatively new area in AIDS research. The update on V-1 Immunitor, the first mucosal AIDS vaccine available commercially as a dietary supplement, is provided within this context.

Vichai Jirathitikal, the chairman of the Immunitor, said: some of our concepts may be disputable, but without departure from the uninspiring consensus no substantial progress in the AIDS vaccine field can be envisioned.

For further information or full version of the article please address: info@immunitor.com
###